Clinical trial · Observational
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
NCT01460641CI-TRIAL-00034739completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- CT perfusion
Primary outcomes (1)
- measure
- Tumor stage change from Computed Tomography (CT) perfusion measurement
- timeFrame
- 3 months
Secondary outcomes (1)
- measure
- Tumor perfusion as measured by perfusion CT.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment. * Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant. * No life expectancy restrictions. * ECOG and Karnofsky Performance Status will not be employed. * Patients with renal failure are ineligible for this study (GFR must be \> 60) * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment. * No restrictions regarding use of other investigational agents. * Patients with severe contrast allergy are ineligible. * Patients who are pregnant or are trying to become pregnant are excluded from this study. * Patients who are cancer survivors or HIV-positive will not be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.